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Introduction {#ecc12392-sec-0001}
============

An experience of prostate cancer can have a significant personal, work‐life and financial impact on men and their families. Despite the prolific body of evidence on prostate cancer diagnoses and treatments, little research exists on the economic burden faced by those directly affected by prostate cancer. Two US studies showed that the majority of expenses occurred during the first 6 months of treatment (Jayadevappa *et al*. [2010](#ecc12392-bib-0011){ref-type="ref"}) and men felt reasonably comfortable in paying up to US\$5000 in medical payments (Jayadevappa *et al*. [2010](#ecc12392-bib-0011){ref-type="ref"}; Markman & Luce [2010](#ecc12392-bib-0016){ref-type="ref"}). Economic burden covers the out‐of‐pocket medical and non‐medical expenses of receiving medical care, the impact on an individual\'s employment situation and on a caregiver\'s employment. Cancer treatments can be prolonged and fragmented across health services and unexpected medical and related expenses can rapidly accrue. Understanding these impacts is important to educate patients about treatments, to support individual health care choices, to help plan and implement social support services and enable equitable and sustainable health policy.

However, in Australia research into out‐of‐pocket expenses is challenging because patterns of care and resource information are not routinely collected in a centralised and linked way. Furthermore, 47% of Australians have optional private health insurance in addition to being covered by national health care insurance (Medicare) and patient out‐of‐pocket costs should be net of this coverage. Despite being open to recall bias, patient self‐report is a practical method of collecting out‐of‐pocket expenses. Self‐reported data have previously occurred through traditional postal and telephone surveys but the development of online survey tools offers new opportunities. Here we report the feasibility, methods and descriptive results of an online cross‐sectional survey on the economic burden experienced by men after a diagnosis of prostate cancer.

Methods {#ecc12392-sec-0002}
=======

Survey development {#ecc12392-sec-0003}
------------------

A number of relevant studies related to this topic were identified (Krahn *et al*. [1999](#ecc12392-bib-0013){ref-type="ref"}, [2009](#ecc12392-bib-0014){ref-type="ref"}; Wilson *et al*. [2006](#ecc12392-bib-0027){ref-type="ref"}; Yabroff *et al*. [2007](#ecc12392-bib-0028){ref-type="ref"}; Warren *et al*. [2008](#ecc12392-bib-0026){ref-type="ref"}; Fourcade *et al*. [2009](#ecc12392-bib-0008){ref-type="ref"}; Roehrborn *et al*. [2009](#ecc12392-bib-0021){ref-type="ref"}; Crawford *et al*. [2010](#ecc12392-bib-0005){ref-type="ref"}; Jayadevappa *et al*. [2010](#ecc12392-bib-0011){ref-type="ref"}; Markman & Luce [2010](#ecc12392-bib-0016){ref-type="ref"}; Skolarus *et al*. [2010](#ecc12392-bib-0022){ref-type="ref"}; Stokes *et al*. [2010](#ecc12392-bib-0023){ref-type="ref"}, [2011](#ecc12392-bib-0024){ref-type="ref"}; Andersson *et al*. [2011](#ecc12392-bib-0002){ref-type="ref"}; Mollinier *et al*. [2011](#ecc12392-bib-0019){ref-type="ref"}) and helped structure our survey, identify the types and sources of expenses incurred and provided guidance on the types and phrasing of questions in our survey. The survey was intended to combine the health situation of respondents and the key economic issues specific to Australian men diagnosed with prostate cancer. To this end, the survey comprised 68 questions over seven domains including: medical history, employment, household finances, out‐of‐pocket expenses of prostate cancer, private health insurance status, quality of life and general socio‐demographic variables. For the questions on out‐of‐pocket expenses, participants were asked how much they spent that was not already covered by Medicare and, if they had one, their private health insurer. A copy of the survey is provided in File S1. The content was informed both by questions used in previous social surveys and developed or adapted by the researchers (Table [1](#ecc12392-tbl-0001){ref-type="table-wrap"}). A final open‐ended question inviting the respondents to provide further information about their experience and/or feedback on the survey was included. The draft survey was circulated to consumers and Prostate Cancer Foundation of Australia (PCFA) executives, with modifications made to structure and wording. The final survey was then pre‐tested online with 15 PCFA members, men with prostate cancer and researchers.

###### 

Survey content and sources

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Section                   Question content                                                                                                                                             Source of questions
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medical history           Diagnosis date, treatments, whether cancer had spread, last PSA test details, concurrent health conditions                                                   Researchers' own questions used in cancer surveys (Gordon *et al*. [2009](#ecc12392-bib-0009){ref-type="ref"}, [2011](#ecc12392-bib-0010){ref-type="ref"}), tailored to prostate cancer

  Employment                Work status, hours of work, leave taken, job performance, major changes at work, retirement choices                                                          Questions used on previous ABS surveys, HILDA surveys\
                                                                                                                                                                                         Researchers' own‐developed questions

  Household finances        Income, benefits, cost impact on family, distress, cost influence on treatment choice, financial hardship indicators, strategies to raise extra funds        ABS social surveys, questions used in Markman and Luce ([2010](#ecc12392-bib-0016){ref-type="ref"})

  Cost of prostate cancer   Costs in the last 3 months, itemised costs, total costs since diagnosis, complications and associated costs, PBS and Medicare Safety Net, CAPS eligibility   Adapted from previous research in Jung *et al*. ([2012](#ecc12392-bib-0012){ref-type="ref"})\
                                                                                                                                                                                         Researchers' own‐developed questions

  Health insurance          Current status, policy duration, treatment coverage, type of hospital treated in, waiting time                                                               Researchers' own‐developed questions

  Quality of life           Five questions on mobility, self‐care, usual activities, pain/discomfort, anxiety/depression, 1 ranking question 0--1 on overall wellbeing                   EuroQol‐5D‐3L (Viney et al. [2011](#ecc12392-bib-0025){ref-type="ref"}) scored using Australian weights

  General characteristics   Age, ethnicity, rurality, language, marital status, education                                                                                                Standard socio‐demographic questions

  Free‐text box             One open‐ended question on any other comments participants wished to make on the financial impact of prostate cancer                                         Researchers' own‐developed question
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ABS, Australian Bureau of Statistics; CAPS, Continence Aids Payment Scheme; HILDA, Household, Income and Labour Dynamics in Australia; PBS, Pharmaceutical Benefits Scheme; PSA, prostate‐specific antigen.

John Wiley & Sons, Ltd

Sampling and recruitment {#ecc12392-sec-0004}
------------------------

We undertook a national online survey of men who self‐reported they had previously been diagnosed with prostate cancer. Sample size calculations indicated 300 respondents were required to detect a large effect size (0.35) in mean costs between equal subgroups with an alpha = 0.05 (two tails) and 80% power. Eligible participants were approached via PCFA and associated support groups, with PCFA hosting a web link to the survey as well as inviting PCFA support group members by email and social media to complete the survey. The membership of PCFA support groups during 2013 included approximately 5000 active members. To capture a broad cross‐section of cancer survivors, no restrictions were made to the time since diagnosis therefore men could be at any time since their diagnosis. Participants were anonymous to the researchers and PCFA staff; no names or other identifying information were collected. The survey period was open until no further responses were received. This happened at 6 weeks after two reminders. Ethical clearance was obtained from Griffith University Human Research Ethics Committee (MED/31/12/HREC).

Data collection and analysis {#ecc12392-sec-0005}
----------------------------

Data were collected online using *LimeSurvey* hosted by the Survey Research Centre at Griffith University. The online survey opened on 8 April 2013 and ran for 6 weeks until 16 May 2013 at which point, after two reminder emails, no further responses were received. Participant consent via a front‐screen information/consent sheet was required to proceed to the survey. Survey results were exported from *LimeSurvey* and analysed in Stata SE/11. Duplicate surveys were manually identified and removed. Subgroup analyses were undertaken between men who were diagnosed prior to January 2012 (more than 16 months prior to the survey date) and since January 2012 (hereafter termed 'recently diagnosed'); between men with and without private health insurance; and by state of residence. Pearson\'s chi‐squared and Student\'s *t*‐tests at *P* \< 0.05 were used to test for significant differences in participant characteristics among subgroups. Skewness was considered for the cost data. Non‐parametric bootstrapped statistics using 1000 repetitions and the bias‐corrected approach was applied to out‐of‐pocket mean costs by subgroups.

Results {#ecc12392-sec-0006}
=======

Responses and missing data {#ecc12392-sec-0007}
--------------------------

A total of 297 survey responses were received. Note that because of the distribution method, which included a web link to the survey, it is not possible to determine the exact number of men who were aware of the survey and hence to calculate the response rate. Respondent self‐reported diagnosis dates ranged from October 1991 up to April 2013, when the survey was completed. Not all participants fully completed the survey, and eight responses were identified as duplicates and subsequently removed from the analysis. Overall, there were 289 individual survey participants, comprising 239 (83%) full and 50 (17%) partial responses. No significant differences in baseline characteristics were found between full and partial responders, except a higher proportion of partial respondents (68%) were diagnosed more than 3 years prior to the survey compared with full responders (51%) *P* = 0.033.

Feasibility of the survey {#ecc12392-sec-0008}
-------------------------

The online survey was acceptable to those respondents who replied with respect to content, format and duration. There were a few exceptions that related to technical issues (in less than 10 men) such as computer 'freezes' or 'crashes', issues hampering the respondent progressing through the survey (related to mandatory responses), and in some cases low computer literacy. While five paper surveys were requested and posted to one support group leader with reply‐paid envelopes, none were returned. A few participants telephoned the researchers to clarify questions, obtain technical support, and in one case provide detailed itemised records of expenses over an 18‐month period.

Respondent characteristics {#ecc12392-sec-0009}
--------------------------

The mean age of respondents was 65 years old. The majority were married or partnered, owned their home and were living in a metropolitan area (Table [2](#ecc12392-tbl-0002){ref-type="table-wrap"}). Thirty‐nine per cent of the men were aged younger than 65 years and most men had other comorbid conditions (e.g. high blood pressure 39%, high cholesterol 30%, arthritis 20%, depression/anxiety 17%). A high proportion of men were university or trade qualified and 38% had household incomes between AU\$37 000 and AU\$80 000. A total of 71% held private health insurance and the mean time with their current insurer was 22.4 years. Just under one quarter (*n* = 65) were recently diagnosed (within 16 months prior to the survey date), with 65% diagnosed in the last 5 years for a median of 3.9 years. The majority had undergone a radical prostatectomy (69%) as primary treatment for their cancer, and many were currently receiving ADT (40%). Less than one fifth indicated their cancer had metastasised.

###### 

Socio‐demographic and clinical profile of respondents

                                                                                    All participants (*n* = 289)   Diagnosed after January 2012[b](#ecc12392-note-0004){ref-type="fn"} (*n* = 65)   Diagnosed before January 2012 (*n* = 224)
  --------------------------------------------------------------------------------- ------------------------------ -------------------------------------------------------------------------------- -------------------------------------------
  Age group                                                                                                                                                                                         
  Mean years (SD)[a](#ecc12392-note-0003){ref-type="fn"}                            65.1 (8.4)                     59.5 (7.5)                                                                       66.9 (7.9)
  \<60 years[a](#ecc12392-note-0003){ref-type="fn"}                                 64 (22)                        30 (46)                                                                          34 (15)
  60--70 years[a](#ecc12392-note-0003){ref-type="fn"}                               110 (38)                       21 (33)                                                                          89 (40)
  70+ years[a](#ecc12392-note-0003){ref-type="fn"}                                  69 (37)                        5 (8)                                                                            64 (28)
  Not stated                                                                        46 (16)                        9 (14)                                                                           37 (17)
  Total                                                                             289 (100)                      65 (100)                                                                         224 (100)
  Marital status[c](#ecc12392-note-0005){ref-type="fn"} (*n*, %)                                                                                                                                    
  Married or *de facto*                                                             220 (90)                       50 (89)                                                                          170 (90)
  Divorced                                                                          13 (5)                         2 (4)                                                                            11 (6)
  Single/Never married/widowed                                                      11 (4)                         4 (7)                                                                            7 (4)
  Education[c](#ecc12392-note-0005){ref-type="fn"}                                                                                                                                                  
  Primary School (Grade 7 or below)                                                 4 (2)                          0 (0)                                                                            4 (2)
  High School (Grade 8 or above)                                                    46 (19)                        10 (18)                                                                          36 (19)
  Dip./Certificate/Trade Qualified                                                  86 (35)                        15 (27)                                                                          71 (38)
  University degree                                                                 108 (44)                       31 (55)                                                                          77 (41)
  Household income[c](#ecc12392-note-0005){ref-type="fn"}                                                                                                                                           
  \<\$18 000                                                                        13 (5)                         3 (5)                                                                            10 (5)
  \$18 201--\$37 000                                                                48 (18)                        7 (12)                                                                           41 (20)
  \$37 001--\$80 000                                                                100 (38)                       20 (33)                                                                          80 (39)
  \$80 000--\$180 000                                                               66 (25)                        20 (33)                                                                          46 (22)
  \>\$180 000                                                                       23 (9)                         4 (7)                                                                            10 (5)
  Unanswered                                                                        17 (6)                         7 (12)                                                                           19 (9)
  Private health insurance, yes                                                     206 (71)                       47 (72)                                                                          159 (71)
  Region[c](#ecc12392-note-0005){ref-type="fn"}                                                                                                                                                     
  Metropolitan                                                                      177 (61)                       41 (63)                                                                          136 (61)
  Regional                                                                          40 (14)                        9 (14)                                                                           31 (14)
  Remote                                                                            13 (4)                         2 (3)                                                                            11 (5)
  Unclear locality                                                                  14 (4)                         4 (6)                                                                            10 (5)
  State[c](#ecc12392-note-0005){ref-type="fn"}                                                                                                                                                      
  New South Wales                                                                   87 (30)                        16 (25)                                                                          71 (32)
  Queensland                                                                        42 (15)                        13 (20)                                                                          29 (13)
  Victoria                                                                          41 (14)                        10 (15)                                                                          31 (14)
  South Australia                                                                   18 (6)                         4 (6)                                                                            14 (6)
  Western Australia                                                                 13 (5)                         1 (2)                                                                            12 (5)
  ACT                                                                               16 (6)                         6 (9)                                                                            10 (5)
  Tasmania                                                                          8 (3)                          1 (2)                                                                            7 (3)
  Northern Territory                                                                5 (2)                          1 (2)                                                                            4 (2)
  Unknown                                                                           59 (26)                        13 (20)                                                                          46 (16)
  Most recent PSA score[d](#ecc12392-note-0006){ref-type="fn"} (ng/mL)              Mean (SD)                                                                                                       
  Metastasised *n* = 48                                                             10.10 (19.6)                   --                                                                               --
  No metastasis *n* = 207                                                           1.5 (5.0)                      --                                                                               --
  Unknown spread of disease *n* = 8                                                 3.5 (6.9)                      --                                                                               --
  Diagnosed in last 3 years                                                         132 (46)                       65 (100)                                                                         67 (30)
  Diagnosed in last 5 years                                                         189 (65)                       65 (100)                                                                         124 (55)
  Prostate cancer metastasised[d](#ecc12392-note-0006){ref-type="fn"}               53 (18)                        11 (17)                                                                          42 (19)
  Comorbidities                                                                                                                                                                                     
  Other cancer                                                                      28 (10)                        3 (5)                                                                            25 (11)
  Heart disease                                                                     24 (8)                         2 (3)                                                                            22 (10)
  Osteoporosis                                                                      22 (8)                         2 (3)                                                                            20 (9)
  Stroke                                                                            5 (2)                          0 (0)                                                                            5 (2)
  Diabetes[a](#ecc12392-note-0003){ref-type="fn"}                                   23 (8)                         1 (2)                                                                            22 (10)
  Arthritis                                                                         59 (20)                        9 (14)                                                                           50 (22)
  High blood pressure                                                               112 (39)                       20 (31)                                                                          92 (41)
  High cholesterol                                                                  88 (30)                        20 (31)                                                                          68 (30)
  Chronic lung disease                                                              7 (2)                          1 (2)                                                                            6 (3)
  Depression/anxiety                                                                49 (17)                        10 (15)                                                                          39 (17)
  Other comorbidities                                                               34 (12)                        8 (12)                                                                           26 (12)
  No. comorbidities per person (*n*, mean)[a](#ecc12392-note-0003){ref-type="fn"}   207 (2.2)                      41 (1.9)                                                                         166 (2.3)
  Treatment completed or current[e](#ecc12392-note-0007){ref-type="fn"}                                                                                                                             
  Watchful waiting                                                                  26 (9)                         3 (5)                                                                            23 (10)
  Active surveillance                                                               38 (13)                        10 (15)                                                                          28 (13)
  Radical prostatectomy                                                             199 (69)                       43 (66)                                                                          156 (70)
  Cytotoxic chemotherapy                                                            9 (3)                          1 (2)                                                                            8 (4)
  Radiotherapy[a](#ecc12392-note-0003){ref-type="fn"}                               89 (31)                        13 (20)                                                                          76 (34)
  Brachytherapy                                                                     18 (6)                         2 (3)                                                                            16 (7)
  Androgen Deprivation therapy                                                      81 (28)                        15 (23)                                                                          66 (29)
  Immunotherapy                                                                     1 (\<1)                        0 (0)                                                                            1 (\<1)
  Other                                                                             22 (8)                         5 (8)                                                                            17 (8)

Values are expressed in *n* (%).

*P* \< 0.05.

Diagnosed in last 16 months prior to survey (January 2012--April 2013).

Data were missing on socio‐demographic and clinical characteristics for 45 (16%) men, including 9 (14%) who were recently diagnosed.

This question is whether a doctor has told the respondent if their cancer has spread 'to other parts of their body' which we assume to mean metastases.

This includes any treatment and therefore the total n does not equal 289.

John Wiley & Sons, Ltd

Out‐of‐pocket costs {#ecc12392-sec-0010}
-------------------

Men who were recently diagnosed reported mean out‐of‐pocket expenditure of 2012 AU\$11 077 (SD \$10 096), with a median of AU\$8000 (interquartile range AU\$14 000) (Table [3](#ecc12392-tbl-0003){ref-type="table-wrap"}). Three quarters of respondents diagnosed since January 2012 reported having spent up to AU\$17 000. Overall, expenditure was largely for specialist fees, hospital services, medical equipment and supplies and medicines. The mean total out‐of‐pocket expenditure reported between diagnosis and survey date by all respondents was AU\$9205 (SD AU\$14 567) with a median \$5000 (interquartile range AU\$10 000). Three quarters of respondents had spent up to AU\$12 000. Respondents with private health insurance reported double the out‐of‐pocket costs (AU\$10 052, 95% CI: AU\$7849--AU\$12 255) than those without insurance (AU\$5103, 95% CI: AU\$2458--AU\$7747) regardless of time since diagnosis. Reported out‐of‐pocket costs were highly right‐skewed with 5% men having high medical expenses (≥AU\$30 000). At the other end of the scale, 5% of the men spent \$250 or less out‐of‐pocket for their prostate cancer treatments. Men who had radical prostatectomy also tended to have higher costs than those managed by active surveillance, watchful waiting or androgen deprivation therapy (Table [3](#ecc12392-tbl-0003){ref-type="table-wrap"}). Reported expenses also tended to be higher among men recently diagnosed (median \$8000) compared with those for men diagnosed within the last 3 years (median \$5500). We found a statistically significant difference in reported cost (unadjusted) between states of residence with the highest median cost being in Queensland (AU\$6500) and the lowest in South Australia (AU\$875).

###### 

Out‐of‐pocket costs by subgroups of patients (Australian dollars)

                                                                                                                    *n*   Mean (SD)             Median (IQR)        Bootstrapped 95% CI[a](#ecc12392-note-0008){ref-type="fn"}
  ----------------------------------------------------------------------------------------------------------------- ----- --------------------- ------------------- ------------------------------------------------------------
  Total expenses since diagnosis (all patients)                                                                     245   \$9205 (\$14 567)     \$5000 (\$10 000)   \$7350--\$11 059
  Diagnosed since January 2012[b](#ecc12392-note-0009){ref-type="fn"} ^,^ [c](#ecc12392-note-0010){ref-type="fn"}   56    \$11 077 (\$10 096)   \$8000 (\$14 000)   \$8395--\$13 759
  Diagnosed in previous 3 years                                                                                     116   \$8923 (\$8750)       \$5500 (\$11 650)   \$7322--\$10 534
  Diagnosed in previous 5 years                                                                                     161   \$8937 (\$10 442)     \$5000 (\$11 500)   \$7401--\$10 473
  Treatment: watchful waiting                                                                                       24    \$5492 (\$5119)       \$3000 (\$8750)     \$3450--\$7534
  Treatment: active surveillance                                                                                    31    \$10 302 (\$12 982)   \$5000 (\$8000)     \$5892--\$14 711
  Treatment: radical prostatectomy                                                                                  171   \$10 996 (\$16 681)   \$6000 (\$11 000)   \$8493--\$13 500
  Treatment: Androgen Deprivation Therapy                                                                           67    \$11 471 (\$24 119)   \$3375 (\$10 300)   \$5765--\$17 177
  Private health insurance                                                                                          196   \$10 052 (\$15 460)   \$6000 (\$9000)     \$7849--\$12 255
  No private health insurance                                                                                       36    \$5103 (\$8022)       \$2000 (\$4000)     \$2458--\$7747
  State: NSW                                                                                                        80    \$10 165 (\$12 038)   \$5750 (\$10 715)   \$7539--\$12 792
  State: Queensland                                                                                                 40    \$14 035 (\$27 290)   \$6500 (\$12 385)   \$5708--\$22 363
  State: Victoria                                                                                                   39    \$5451 (\$5095)       \$5000 (\$6900)     \$3944--\$6959
  State: South Australia                                                                                            18    \$3458 (\$7088)       \$875 (\$2100)      \$323--\$6592
  Advanced prostate cancer                                                                                          43    \$12 328 (\$15 977)   \$5000 (\$10 000)   \$7498--\$17 159

Non‐parametric bootstrapping with 1000 repetitions and the bias‐corrected approach -- 95% confidence interval around mean.

Diagnosed in last 16 months from survey January 2012--April 2013.

\$AUD 2012. For all other subgroups, the dollars are unadjusted for inflation as we do not have information in which years the costs were incurred.

John Wiley & Sons, Ltd

Employment impact {#ecc12392-sec-0011}
-----------------

A total of 107 (39%) participants reported that they were in the workforce at the time of the survey. Approximately one quarter of men stated that they chose an earlier retirement age, and had stopped work, as a result of their diagnosis (Table [4](#ecc12392-tbl-0004){ref-type="table-wrap"}). On average, respondents who had retired early had retired 4--5 years earlier than planned. There was also a reduction in employment among respondents diagnosed in the 16 months prior to the survey with 17% reducing their work hours and 17% stopping work. Also, those recently diagnosed reported longer usual work hours but more had missed work for illness compared with all respondents. In their workplace, most respondents indicated that they had been treated with respect and support when diagnosed with prostate cancer. In a few instances, respondents indicated that they had been passed over for promotion (six men, 2%), had not told their employer about their cancer (five men, 2%) or had been made redundant (nine men, 3%).

###### 

Employment status and impact from prostate cancer

                                                                                                                      All participants (*n* = 289)   Diagnosed after January 2012[b](#ecc12392-note-0013){ref-type="fn"} (*n* = 65)   Diagnosed before January 2012 (*n* = 224)
  ------------------------------------------------------------------------------------------------------------------- ------------------------------ -------------------------------------------------------------------------------- -------------------------------------------
  Current work status[a](#ecc12392-note-0012){ref-type="fn"}                                                                                                                                                                          
  Retired                                                                                                             152 (55)                       21 (33)                                                                          131 (61)
  Employed                                                                                                            107 (38)                       36 (50)                                                                          71 (33)
  Unemployed/Other                                                                                                    19 (7)                         6 (20)                                                                           13 (6)
  Missing                                                                                                             11 (--)                        2 (--)                                                                           9 (--)
  Work status prior to diagnosis                                                                                                                                                                                                      
  Retired                                                                                                             71 (26)                        13 (21)                                                                          58 (27)
  Employed                                                                                                            196 (71)                       47 (75)                                                                          149 (70)
  Unemployed/Other                                                                                                    10 (4)                         3 (5)                                                                            7 (3)
  Missing                                                                                                             12 (--)                        2 (--)                                                                           10 (--)
  Impact on retirement age                                                                                                                                                                                                            
  Did diagnosis affect retirement age?                                                                                                                                                                                                
  No, retired when I expected / expect to retire as planned                                                           196 (71)                       42 (67)                                                                          154 (72)
  Yes, my cancer meant I chose a later retirement age                                                                 16 (6)                         5 (8)                                                                            11 (5)
  Yes, my cancer meant I chose an earlier retirement age                                                              64 (23)                        16 (25)                                                                          48 (23)
  Missing                                                                                                             13 (--)                        2 (--)                                                                           11 (--)
  Change in work since diagnosis[c](#ecc12392-note-0014){ref-type="fn"} ^,^ [d](#ecc12392-note-0015){ref-type="fn"}                                                                                                                   
  Decreased work hours                                                                                                41 (14)                        11 (17)                                                                          30 (13)
  Increased work hours                                                                                                10 (3)                         3 (5)                                                                            7 (3)
  Change in income                                                                                                    40 (14)                        8 (12)                                                                           32 (14)
  Change in role/responsibilities                                                                                     28 (10)                        5 (8)                                                                            23 (10)
  Change in employer                                                                                                  17 (6)                         2 (3)                                                                            15 (7)
  Stopped work[a](#ecc12392-note-0012){ref-type="fn"}                                                                 77 (27)                        11 (17)                                                                          66 (29)
  No change to work                                                                                                   138 (48)                       34 (52)                                                                          104 (46)
  Work environment experience[c](#ecc12392-note-0014){ref-type="fn"}                                                                                                                                                                  
  Colleagues treated me differently[a](#ecc12392-note-0012){ref-type="fn"}                                            20 (7)                         10 (15)                                                                          10 (5)
  Passed over for promotion                                                                                           6 (2)                          2 (3)                                                                            4 (2)
  Demoted                                                                                                             1 (0)                          0 (0)                                                                            1 (\<1)
  Made redundant                                                                                                      9 (3)                          4 (6)                                                                            5 (2)
  Treated with respect and support                                                                                    109 (38)                       30 (46)                                                                          79 (35)
  Did not reveal prostate cancer at work                                                                              5 (2)                          1 (2)                                                                            4 (2)
  Other work impact                                                                                                   36 (12)                        8 (12)                                                                           28 (12)
  Not applicable (i.e. not working)                                                                                   125 (43)                       23 (35)                                                                          102 (40)

Values are expressed in *n* (%).

*P* \< 0.05.

Diagnosed within 16 months prior to survey (January 2012--April 2013).

Not mutually exclusive categories.

The question was phrased 'since your diagnosis of prostate cancer' therefore it is possible that changes may not have been 'due to' the prostate cancer.

John Wiley & Sons, Ltd

Financial impact {#ecc12392-sec-0012}
----------------

In assessing participants who were recently diagnosed, 57% of respondents indicated that their financial position was 'reasonably comfortable'. However, six men (9%) stated that they decided against treatment due to its high expense. Even so, 70% had spent more for their cancer treatment than they expected to, 20% said that the cost of treating their prostate cancer had caused them 'a great deal' of distress. One‐third of participants (34%) reported they were 'just getting on' or 'struggling' financially. To pay for their treatment, respondents reported they had drawn on savings (38%), sold assets (8%) and increased a credit card limit (22%). Reporting unfavourable financial impacts of prostate cancer treatment appeared to be worse for men who were recently diagnosed compared with the responses of all respondents. In total, 206 (71%) had private health insurance and most of these men were treated in a private hospital (171 or 83%) with the remainder treated in the public sector (35 or 17%). General comments received from respondents add further insight to the survey results and provide useful supplementary data to understanding respondents' experience with the financial impact of prostate cancer (File S2).

Discussion {#ecc12392-sec-0013}
==========

Our study found that 50% of men diagnosed during 2012 reported out‐of‐pocket expenses of up to AU\$8000 for their prostate cancer treatment while 75% of men spent up to AU\$17 000 (2012). Despite the caution required when interpreting our findings from a select group of men with prostate cancer, they suggest a large variability in out‐of‐pocket medical costs for prostate cancer treatment with some men facing very high costs. Notably, many study participants were well‐educated, financially comfortable and two‐thirds were privately insured but this did not provide adequate protection for the costs related to this unexpected but common disease. It is known that patterns of treatment vary between the public and private systems and between states (Evans *et al*. [2013](#ecc12392-bib-0007){ref-type="ref"}). Many experts also believe that consumerism has had an impact on treatment choices for prostate cancer, which has in turn impacted costs (Alkhateeb & Lawrentschuk [2011](#ecc12392-bib-0001){ref-type="ref"}). It seems likely that these factors contribute, at least to some degree, to the variability of costs in our study.

While the financial considerations of health care will naturally be of secondary importance when a person is told he has cancer and needs treatment, these findings highlight this to be an additional source of distress at a vulnerable time. Some individuals face considerable financial consequences after a diagnosis of cancer and they are unable to work or face high out‐of‐pocket expenses. When addressing supportive care needs, it is becoming increasingly important to consider the patient\'s financial position and where necessary, provide adequate support and/or referrals to local support agencies. When diagnosed with prostate cancer men should be made aware of their financial options and the sources of assistance that may alleviate this distress and avoid later decisional regret. Earlier awareness of what services are or are not covered by private health insurance policies and switching private health insurers to obtain improved coverage may also be advisable.

Private health insurance is designed to help consumers manage health care expenses but it does not protect them from open‐ended co‐payments (e.g. specialist fees, hospital fees) leaving individuals exposed to unlimited costs (Doggett [2014](#ecc12392-bib-0006){ref-type="ref"}). There has also been a trend towards private health insurance policies with lower premiums, but more restrictions and exclusions for selected treatments, leading to higher co‐payments when insurance is used (Doggett [2014](#ecc12392-bib-0006){ref-type="ref"}). A recent patterns of care study in Victoria (Evans *et al*. [2013](#ecc12392-bib-0007){ref-type="ref"}), that recruited men with prostate cancer from the Victorian registry, reported the changes in treatment during the past decade. They identified declines in the proportion of men treated with first‐line ADT (6% from 39%), increases in curative treatments such as surgery, radiotherapy or brachytherapy (71% from 25%), increases in EBRT and high‐dose brachytherapy (26% from 12%) and expected increases in robotic surgery (currently 20% of all radical prostatectomies). These trends were similar to those reported in Queensland and NSW studies (Evans *et al*. [2013](#ecc12392-bib-0007){ref-type="ref"}) but may be different to those in South Australia which has experienced stable rates in prostatectomy (23%). What is different across states is the level of private health insurance coverage (i.e. ACT 58%, NSW 48%, QLD 45%, VIC 45% NT 39% and Australia‐wide 47% in 2014) ([www.phiac.gov.au](http://www.phiac.gov.au)). In combination with the different fees charged by doctors, the varied hospital costs passed on to patients and different gap schemes of private health insurers, this is likely to influence the variation in patient co‐payments.

Latest figures indicate that average household expenditure on goods and services in Australia was \$1236 per week in 2009--2010 which rose \$343 per week (38%) since 2003--2004 (Australian Bureau of Statistics [2003](#ecc12392-bib-0003){ref-type="ref"}). Although the spending on 'medical care and health expenses' also rose during this time by 40%, it is still below spending on housing, food, transport, miscellaneous goods and services (which includes education costs), and recreation categories (Australian Bureau of Statistics [2003](#ecc12392-bib-0003){ref-type="ref"}). On average, individual medical out‐of‐pocket expenses in Australia are higher than those in most European countries, are growing on average 6.7% annually, and represent 17.8% of overall health care funding (Australian Institute of Health and Welfare [2013](#ecc12392-bib-0004){ref-type="ref"}). Also, due to Australia\'s geography, travel and accommodation expenses would not affect most Europeans. These factors suggest that the findings presented here are high relative to those experienced by most European residents. Co‐payments are known to be a less equitable form of health funding and will potentially increase health inequality across socio‐demographic groups (Pisu *et al*. [2010](#ecc12392-bib-0020){ref-type="ref"}; Meneses *et al*. [2012](#ecc12392-bib-0018){ref-type="ref"}; Lauzier *et al*. [2013](#ecc12392-bib-0015){ref-type="ref"}; Doggett [2014](#ecc12392-bib-0006){ref-type="ref"}). Calls have been made for a national framework for co‐payment policy which currently does not exist (Doggett [2014](#ecc12392-bib-0006){ref-type="ref"}).

Despite there being a paucity of research in this area, US researchers have examined the direct and indirect health care expenditures for cancer (Pisu *et al*. [2010](#ecc12392-bib-0020){ref-type="ref"}; Meneses *et al*. [2012](#ecc12392-bib-0018){ref-type="ref"}; Lauzier *et al*. [2013](#ecc12392-bib-0015){ref-type="ref"}) and have recently called it the 'financial toxicity' of cancer treatment (Mcdougall & Ransey [2014](#ecc12392-bib-0017){ref-type="ref"}). Our research complements two US‐based studies quantifying the personal cost of prostate cancer treatment to patients (Jayadevappa *et al*. [2010](#ecc12392-bib-0011){ref-type="ref"}; Markman & Luce [2010](#ecc12392-bib-0016){ref-type="ref"}). One found approximately 80% of patients with prostate cancer experienced average out‐of‐pocket costs of up to US\$5000 (Markman & Luce [2010](#ecc12392-bib-0016){ref-type="ref"}). However, cost varied with treatment type (Jayadevappa *et al*. [2010](#ecc12392-bib-0011){ref-type="ref"}), with the majority of treatment costs occurring soon after diagnosis for younger men, those with advanced cancer, and those undergoing surgical interventions.

The retrospective and cross‐sectional nature of survey leaves the results open to recall bias to an unknown degree. There was a wide variation between respondents in the time between diagnosis and survey date, making the accurate recall and interpretation of cumulative costs difficult. The variation across respondents in the time between diagnosis and survey date is likely to contribute to the range of costs reported. However, we designed the survey to focus on the actual impact of the financial burden to individuals rather than strive for accuracy of the dollar value. Clearly, an improvement to our design would be to prospectively capture medical expenses at frequent intervals (e.g. 3 monthly), validate with receipts and anchor participants at recruitment to a common starting time (e.g. within 3 months of diagnosis). This more intensive design would incur a high burden on participants and may lower completion rates.

Our survey captured a sample of 289 men covering a broad spectrum of ages, geographic regions and socio‐economic status. However, while it drew from the entire nation, the study was not population‐based and generalisability is not guaranteed. Compared with an Australian population‐based sample in study (Evans *et al*. [2013](#ecc12392-bib-0007){ref-type="ref"}), the mean age was 66.2 years compared with our study mean age 56 years, 44% had radical prostatectomy versus our study of 66% and 50% had private insurance versus 72% in our study. The questions on costs were framed specifically to minimise inaccuracies (e.g. 'SINCE DIAGNOSIS, how much would you estimate to have spent in TOTAL for your prostate cancer out of your own money? I.e. the amount you paid that was not covered by Medicare or your health insurance.'). However, we cannot rule out problems with the accuracy (over or under estimates) of the expenses reported by the participants. Some men said they had referred to receipts, tax and other written documents to support their answers. There was higher participation among those with private health insurance and those with good computer literacy. Also, participants were drawn from PCFA prostate cancer support groups and they are likely to have been more interested and engaged with the topic, and potentially had higher‐than‐normal medical expenses. The PCFA only attracts a very small proportion of the overall Australian men living with prostate cancer (\~5000 members from at least 120 000 prevalent cases). On the other hand, the study did provide a balanced view with many men saying they had had low financial burdens. Finally, we relied on self‐report of prostate cancer and had no way of verifying the diagnosis of prostate cancer among respondents. However, a targeted approach was taken and we have no reason to believe that respondents did not have prostate cancer.

We have demonstrated that an online format is acceptable and feasible to some men with prostate cancer. Advantages include online surveys are quickly, widely and cheaply disseminated, require no data entry, allow privacy and mandatory response types can minimise missing data. However, these advantages come at the expense of still requiring data cleaning, survey incompletions, some technical difficulties and men required to be competent using a computer. We found that providing space for respondents' free comments resulted in a deeper understanding of responses. Until further assessment of the psychometric properties of this survey is undertaken, the complexity of this topic, combined with the variation in participant experiences here suggests a mixed methods approach is optimal.

There are significant research gaps in our understanding of how medical out‐of‐pocket expenses and other economic burdens impact on individuals. This study provides a starting point and snapshot into this area for men with prostate cancer. Although, it is not traditionally viewed as a chronic disease, high survival rates mean there is ongoing health care resources beyond the upfront primary treatment (e.g. secondary treatments, bone scans, PSA tests). Furthermore, many men in our survey had other chronic illnesses such as diabetes, arthritis, depression and heart disease. The financial burden imposed by prostate cancer for these individuals was compounding. This study highlights the problem of cumulative out‐of‐pocket costs and the need for policy debate ahead of proposed changes in Australia to Medicare doctor and medication co‐payments. Financial hardship did exist for some men in our study and many had a reduced capacity to work, exacerbating the individual\'s financial distress.
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